Eighteen months after the ACCORD (Action to Control Cardiovascular Risk in Diabetes ) trial found no benefit for the addition of fenofibrate to simvastatin in patients with type 2 diabetes, the FDA has issued a safety communication. The FDA changed the label for Trilipix (fenofibric acid, Abbott) and is notifying healthcare […]
